Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.40 |
| ▸ | PRSS8 | Q16651 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463419 | 0.90 | CTSS (0.48) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL6465141 | 0.90 | CTSS (0.48) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL6468629 | 0.90 | CTSS (0.48) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL6464884 | 0.89 | CTSS (0.49) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL7049339 | 0.88 | CTSS (0.53) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL7049425 | 0.88 | CTSL (0.49) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL7043392 | 0.87 | DAGLA (0.55) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL6464300 | 0.85 | CTSS (0.44) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL6465745 | 0.83 | KMT2A (0.43) | CTSSCTSLCTSBKMT2ALMNA | |
| SCHEMBL7047962 | 0.83 | KMT2A (0.44) | CTSSCTSLCTSBCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885CTSL 18/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.